source
- Sanofi eyes 'moonshot' drug acquisitions to offset upcoming Dupixent patent lossSanofi's CFO Francois-Xavier Roger told Fierce that the company is looking at 'moonshot' treatments as potential acquisition targets to rebuild its pipeline. The push comes as the U.S. patent on D…
- Merck says 2027 will focus on pipeline and new product launches despite recent trial winsMerck's chief financial officer said the company views 2027 as another year of investment, emphasizing its expanding pipeline and upcoming product launches rather than short‑term margin growth. Th…